Describing the Clinical and Economic Burden of Women Diagnosed With Uterine Fibroid (UF) and Heavy Menstrual Bleeding (HMB) in a United States (US) Commercial Database 2015-2022

Author(s)

McKain L1, Brady B2, Tran AT3, Lickert C4
1McKain Consulting, LCC, San Antonio, TX, USA, 2Merative, Laurel, MD, USA, 3Merative, Ann Arbor, MI, USA, 4Sumitomo Pharma America, Inc, FLOSSMOOR, IL, USA

OBJECTIVES: Uterine fibroids are common benign tumors. The objective is to describe the current clinical and economic burden of women diagnosed with UF only and UF with HMB.

METHODS: A retrospective, observational study using the MerativeTM MarketScan® Commercial Database (2015-2022) identified women 18-55 years old newly diagnosed with UF with and without HMB. Cohorts were defined based on claim order: UF then HMB (UF-HMB), HMB then UF (HMB-UF), UF only and age matched 1:1:1; control (non-UF and non-HMB) cohort was age matched 5:1. Healthcare resource utilization and costs were assessed in the 12 months prior and following the first UF claim (UF cohorts) or a randomly assigned Obstetrician/gynecology visit (non-UF/non-HMB cohort).

RESULTS: The study included 22,057 women in each UF cohorts and 110,285 controls; all cohorts mean age was 43.5 years. Pre-UF diagnosis > 40% of patients in each UF cohort had > 1 bulk symptom. Post-UF diagnosis bulk symptoms increased in all UF cohorts ranging from 54-64%, with the most common being pelvic pressure/pain (36-49%), backache (17%) and urinary frequency/incontinence (11-13%). The HMB cohorts had the highest clinical burden post-UF diagnosis compared to UF only and the control group. Treatment patterns, following UF diagnosis demonstrated 18-38% received no pharmacological therapy of interest, < 30% received hormonal therapy, with oral contraceptives (15-20%) being the most common; a surgical/gynecological procedure occurred in < 57%, with hysterectomy (11-34%) being the most common.

The HMB-UF ($21,993±$31,189) and UF-HMB ($21,119±$28,772) cohorts had significantly higher all-cause post-UF diagnosis total costs compared to patients with UF only ($16,491±$36,111); all p<0.001. Total costs increased > 2 -fold from the pre- to post-UF diagnosis for all UF cohorts. Outpatient costs accounted for >50% of total costs pre- and post-diagnosis.

CONCLUSIONS: Results of this study demonstrate a notable clinical and economic burden of UF, with HMB exacerbating the incremental burden over UF alone.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

EE324

Topic

Clinical Outcomes, Economic Evaluation, Study Approaches

Topic Subcategory

Clinician Reported Outcomes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Reproductive & Sexual Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×